Luneau Technology, a portfolio company of Caravelle, has acquired Optovue
Founded in 2003 and headquartered in California, Optovue is a leader in eye care technology dedicated to the advancement and commercialization of high-speed optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) technology, which are used to facilitate the diagnosis and management of eye diseases. Optovue was the first to market spectral domain OCT in the United States and now deploys its technology worldwide.
Founded in 1928 and headquartered in France, Luneau is a global leader in the optical industry that develops, manufactures and markets innovative devices for optometrists, ophthalmic and optical professionals with products based on its patented WAVEFRONT technology. The company’s flagship brand, VISIONIX, is a key embodiment of this technology. Since 2019, Luneau has been majority-owned by Caravelle, a diversified family-owned group based in France.
The two companies are perfectly matched to create a global platform delivering a world-class, complete offering for eye care physicians and transform access to visual health for patients. This combination will allow Optovue and Luneau to leverage their industry expertise, strengthen their international footprint and provide customers with game-changing solutions spanning a full product range. Their joint vision is to be the first-choice partner for primary eye care physicians and to significantly optimize access to visual health for patients across the globe.
Tony Crisman, Managing Director at Lincoln, added, “It was an honor working with the leaders at Luneau and Caravelle on this important merger that supports their long-term global growth strategy and goals.”
Lincoln acted as the exclusive investment banking advisor to Luneau, working closely with the company’s management team and shareholders throughout the process.
Lincoln played a critical role in helping us structure a deal that worked for us, our shareholders and the various Optovue shareholders. Additionally, their ability to manage the diligence workstreams and provide strategic guidance on both the process and the United States market dynamics were critical to achieving a successful outcome.
Meet our Senior Team
View More Transactions in Healthcare
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.